CHIRON® RECOMBINANT PROTEINS
A LOCAL PARTNER IN THE SAN FRANCISCO BAY AREA
The biomanufacturing legacy of the Grifols campus in Emeryville, California, began with Chiron and Cetus in the 1980s, with innovative advancements in yeast expression, viral discovery and the development of PCR. Three decades of process development and manufacturing experience is the foundation of the business today at CHIRON® Recombinant Proteins.
CHIRON® Recombinant Proteins partners with companies interested in developing complex proteins into therapeutics, vaccines or diagnostics. Our state-of-the-art GMP biological manufacturing CMF facility located in the San Francisco Bay Area is well positioned to provide long-term, high-quality, commercial manufacturing of recombinant biologic drug substances to our customers, regardless of their global location. This location, in one of the major U.S. biotech hubs –– home to many emerging biotechnology companies lacking extensive internal development and manufacturing resources –– provides us with an opportunity to effectively serve a host of local customers.
CHIRON® Recombinant Proteins is staffed by highly experienced and talented people with diverse expertise and educational backgrounds within the field of biotechnology. Our staff welcomes the opportunity to have face-to-face visits with clients where new ideas can be discussed. With their significant tech transfer expertise and access to the state-of-the-art facilities and equipment within the CMF and new pilot plant, including R&D, process development and analytical laboratories, our scientists can rapidly identify solutions for our CDMO clients.
Grifols is a global healthcare company founded in Barcelona in 1940, committed to improving the health and well-being of people around the world. We produce essential plasma medicines for patients to treat rare, chronic and, at times, life-threatening conditions. The company provides a comprehensive portfolio of solutions in transfusion medicine and also offers hospitals, pharmacies and healthcare professionals information and services that deliver efficient, expert medical care.
The biopharma industry has been challenged to discover and develop new diagnostic tests, treatments, and vaccines to help resolve the pandemic. Learn how one CDMO embraces the challenge.
Organizations developing products requiring fermentation often create custom processes from scratch, leaving room for inefficiencies, lost value, and, in the case of significant error, costly time delays.
Learn how a CDMO helps biopharma organizations predict and mediate technical transfer risks before they become costly, time-consuming problems.
Grifols Recombinant Protein CDMO, in Emeryville, California, produces recombinant proteins for therapeutics and diagnostics. With services ranging from concept to process development to GMP manufacturing, we look forward to partnering with you to bring your vision to life, together.
Seven diverse experts discuss how Grifols Recombinant Protein CDMO's legacy and recent investments support its future in providing recombinant protein CDMO services.
Choosing a CDMO that is agile, innovative, and exhibits a willingness to invest in new equipment, infrastructure and services will allow the innovator company and the CDMO to grow together.
Successful and rapid analytical method development plays a key role in ensuring the development of robust processes to produce high-quality products.
The result of regulatory compliance with quality standards is binary, but the processes employed to get there don't need to be rigid, inefficient, and expensive. Learn how innovation drives efficiencies.
Grifols New Manufacturing Facility Provides Contract Development And Manufacturing Solutions For Recombinant Proteins
Grifols' Consolidated Manufacturing Facility (CMF) is a flexible, multiproduct facility with available manufacturing capacity that created an opportunity to leverage their existing technical expertise and commitment to quality to provide contract services to biopharma companies as a recombinant protein CDMO and support the development of innovative therapies. We recently spoke with Paul Magreta at Grifols about their new $80 million manufacturing facility in Emeryville, California, and the CDMO Services they offer.
Grifols Achieves Key Milestone With FDA Approval Of The New Consolidated Manufacturing Facility (CMF) For Production Of Recombinant Proteins
Emeryville, CA - Grifols (MCE: GRF, MCE: GRF.P andNASDAQ: GRFS), a global healthcare company with a history of more than 75 years of improving people's health and well-being and a leader in the development of innovative diagnostic solutions, recently received approval from the U.S. Food & Drug Administration to relocate existing immunodiagnostic manufacturing operations to a new Consolidated Manufacturing Facility (CMF) in Emeryville, California